- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06027788
Prova di protezione embolica CTSN (EMPRO)
Protezione embolica in pazienti sottoposti a chirurgia valvolare ad alto rischio
This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is a prospective, multicenter, randomized controlled clinical trial that will evaluate the effectiveness and safety of the CardioGard embolic protection cannula compared to a standard cannula. The enrollment period is expected to last 30 months, and all patients will be followed for 12 months post procedure.
RANDOMIZATION Patients will be randomized 1:1 to the embolic protection device or to a standard cannula in the operating room (OR) immediately after sternotomy and confirmation by the surgical team of the patient's suitability for the proposed intervention (CardioGard embolic protection device). Randomization will be with equal allocation and stratified by site and by procedure (i.e., isolated valve surgery or combined procedures, such as double valve or valve plus coronary artery bypass grafting, CABG). The randomization assignment will be controlled centrally and performed through a web-based data collection system that automates the delivery of the randomization codes. From the point of treatment assignment, primary efficacy will be analyzed by intention-to-treat; that is, the patients will be grouped by their assignments at randomization regardless of whether or not they actually received the treatment to which they were assigned.
STUDY POPULATION The patient population for this trial consists of patients age ≥ 60 undergoing different types of valve surgery with or without CABG via full or minimal-access sternotomy using legally marketed valve(s). Specific inclusion and exclusion criteria are listed below. All patients who meet the eligibility criteria may be included in the study regardless of gender, race, or ethnicity.
SUBSTUDY Sleep Disturbance Ancillary Sub-Study - Patients undergoing surgery for valvular heart disease (VHD) are at high risk for adverse events, including high rates of post-operative delirium (POD). Should circadian disruption be found to be an important predictor in this high-risk population, safe, low cost, and easy to administer therapies to regulate circadian rhythm such as light therapy could be evaluated in future studies
The aims of this ancillary sub-study include:
- To investigate the association between short sleep duration, less sleep regularity, and greater circadian rhythm disruption prior to surgery and POD within 7 days of VHD surgery.
- To investigate the association between short sleep duration, less sleep regularity and greater circadian rhythm disruption (reduced melatonin and cortisol amplitudes) after surgery and POD within 7 days of VHD surgery.
Approximately 300 EMPRO trial participants will be enrolled into the ancillary study. The study is being conducted in highly experienced clinical centers in the U.S. and Canada. The estimated enrollment period is 12-15 months.
All eligible and consented patients in the parent EMPRO trial will be offered enrollment in this ancillary study through the parent trial consent process.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Ontario
-
London, Ontario, Canada
- London Health Sciences Centre
-
Ottawa, Ontario, Canada
- University of Ottawa Heart Institute
-
-
Quebec
-
Montreal, Quebec, Canada
- Montreal Heart Institute
-
Québec, Quebec, Canada, QC G1V 4G5
- Hôpital Laval
-
-
-
-
Arkansas
-
North Little Rock, Arkansas, Stati Uniti, 72117
- CHI St. Vincent Heart Institute
-
-
California
-
Los Angeles, California, Stati Uniti, 90033
- Keck Hospital of the University of Southern California
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Emory University
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70506
- Ochsner Clinic
-
-
Maine
-
Portland, Maine, Stati Uniti, 04102
- Maine Medical Center
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Johns Hopkins Medicine
-
College Park, Maryland, Stati Uniti, 20742
- University of Maryland
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- University of Michigan
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti, 55905
- Mayo Clinic
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64111
- Saint Luke's Hospital of Kansas City
-
-
New York
-
New York, New York, Stati Uniti, 10032
- Columbia University Medical Center
-
New York, New York, Stati Uniti, 21287
- Northwell Health
-
The Bronx, New York, Stati Uniti, 10467
- Montefiore Medical Center
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27710
- Duke University
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45267
- University of Cincinnati Medical Center
-
Cleveland, Ohio, Stati Uniti, 44195
- Cleveland Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Hospital of the University of Pennsylvania
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22903
- University of Virginia
-
-
West Virginia
-
Morgantown, West Virginia, Stati Uniti, 26506
- West Virginia University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Age ≥ 60 years
-
Planned de novo or redo:
- Surgical aortic valve replacement SAVR ± ascending aortic repair (if circulatory arrest is not required) ± CABG
- Mitral valve replacement (MVR) ± CABG
- Mitral Valve Repair + CABG,
- Double/Triple valve surgery ± CABG; Ross procedure These procedures can be done via a full or minimal-access sternotomy (using central aortic perfusion cannulae) with legally marketed valve(s), and can be done in combination with an left atrial appendage (LAA) closure/excision or partial/complete Maze procedure.
- Valve sparing aortic root replacement (David procedure)
- Valve sparing aortic root replacement (David procedure)
-
No evidence of neurological impairment as defined by a NIHSS ≤1 and modified Rankin scale (mRS) ≤2 within 30 days prior to randomization
-
Ability to provide informed consent and comply with the protocol
Exclusion Criteria:
- History of clinical stroke within 3 months prior to randomization
- Cerebral and or aortic arch arteriography or interventions within 3 days of the planned procedure
- Coronary catheterization within 3 days of index procedure, and the required repeat NIHSS score post-catheterization is worse than the screening/baseline NIHSS score conducted prior to the catheterization
- Active endocarditis at time of randomization with vegetation criteria
- Clinical signs of cardiogenic shock or treatment with IV inotropic therapy prior to randomization
- Participation in an interventional (drug or device) trial
- Isolated mitral valve repair, isolated tricuspid valve repair or combined mitral valve repair and tricuspid valve repair
- Anticipated requirement for prolonged mechanical ventilation greater than 48 hours after surgery in the opinion of the investigator
- Planned concomitant carotid endarterectomy during index surgical procedure
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: CardioGard Embolic Protection Cannula
In patients assigned to the embolic protection device group, the CardioGard Embolic Protection Cannula is used instead, according to the manufacturer's instructions for use (IFU). |
The CardioGard embolic protection cannula is a device that combines the function of a standard aortic cannula with an added suction mechanism to capture debris that may result from cardiac surgery. The device is comprised of 2 hollow tubes. The first tube is the standard main forward-flow tube to return oxygenated blood to the patient's aorta. The second tube attached to an existing bypass vent port, is a novel element located posteriorly to the main tube; its function is to facilitate blood and particle suction by directing the blood back to the reservoir of the coronary bypass machine, while the retrieved embolic debris is eliminated through the filter of the venous reservoir. |
|
Comparatore placebo: Standard Aortic Cannula
In patients assigned to the standard cannula group, standard cannulation techniques are performed using any standard aortic cannula of the surgeon's choice |
An aortic cannula is a device that is used routinely during cardiac surgery to return oxygenated blood from the cardiac bypass machine into the patient's aorta. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of patients who experience ischemic stroke and Acute Kidney Injury (AKI)
Lasso di tempo: within 3 days post-randomization
|
The combined number of patients who experience clinical ischemic strokes and acute kidney injuries that have occurred within 3 days post-randomization. |
within 3 days post-randomization
|
|
Number of patients who experience of death and delirium
Lasso di tempo: by 7 days post-randomization
|
The combined number of patients who experience death and delirium by 7 days post-randomization (with a blanking period for delirium of days 1 and 2 post-operatively). |
by 7 days post-randomization
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of patients who experience a clinical ischemic stroke
Lasso di tempo: within 3 days post-randomization
|
The proportion of patients who experience a clinical ischemic stroke within 3 days will be compared between the two groups (i.e., standard cannula versus the CardioGard device). |
within 3 days post-randomization
|
|
Proportion of patients who experience a clinical ischemic stroke
Lasso di tempo: within 7 days post-randomization
|
The proportion of patients who experience a clinical ischemic stroke within 7 days will be compared between the two groups (i.e., standard cannula versus the CardioGard device). |
within 7 days post-randomization
|
|
Number of patients with disabling clinical stroke
Lasso di tempo: within 3 days post-randomization
|
Number of patients with disabling clinical stroke within 3 days post-randomization |
within 3 days post-randomization
|
|
Number of patients with disabling clinical stroke
Lasso di tempo: within 7 days post-randomization
|
Number of patients with disabling clinical stroke within 7 days post-randomization |
within 7 days post-randomization
|
|
Neurological outcomes assessed by National Institutes of Health Stroke Scale (NIHSS)
Lasso di tempo: within 3 days post-randomization
|
Neurological outcomes are assessed by National Institutes of Health stroke Scale (NIHSS) to compare the treatment outcomes of three types of service delivery models. The NIHSS is an 11-item impairment scale to evaluate neurologic outcome and degree of recovery. Each item is scored between 0 and up to 4, total score ranges 0 (normal function) and a maximum possible score 42, with higher score indicating higher level of impairment. These assessments will be administered by blinded neurology trainees or study coordinators who are certified to administer the assessments. |
within 3 days post-randomization
|
|
Neurological outcomes assessed by National Institutes of Health Stroke Scale (NIHSS)
Lasso di tempo: within 7 days post-randomization
|
Neurological outcomes are assessed by National Institutes of Health stroke Scale (NIHSS) to compare the treatment outcomes of three types of service delivery models. The NIHSS is an 11-item impairment scale to evaluate neurologic outcome and degree of recovery. Each item is scored between 0 and up to 4, total score ranges 0 (normal function) and a maximum possible score 42, with higher score indicating higher level of impairment. These assessments will be administered by blinded neurology trainees or study coordinators who are certified to administer the assessments. |
within 7 days post-randomization
|
|
Number of patients with disabling clinical stroke determined by modified Rankin Scale (mRS) score ≥2
Lasso di tempo: at baseline
|
Number of patients with disabling clinical stroke as indicated by mRS score ≥2. mRS will be assessed at baseline days. The scale runs from 0-6, running from perfect health without symptoms to death. A higher score indicates greater impairment. 0 - No symptoms.
3. - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to walk and attend own bodily needs without assistance. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead. |
at baseline
|
|
Number of patients with disabling clinical stroke determined by modified Rankin Scale (mRS) score ≥2
Lasso di tempo: at 30 days
|
Number of patients with disabling clinical stroke as indicated by mRS score ≥2. mRS will be assessed at 30 days. The scale runs from 0-6, running from perfect health without symptoms to death. A higher score indicates greater impairment. 0 - No symptoms.
3. - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to walk and attend own bodily needs without assistance. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead. |
at 30 days
|
|
Number of patients with disabling clinical stroke determined by modified Rankin Scale (mRS) score ≥2
Lasso di tempo: at 90 days
|
Number of patients with disabling clinical stroke as indicated by mRS score ≥2. mRS will be assessed at 90 days. The scale runs from 0-6, running from perfect health without symptoms to death. A higher score indicates greater impairment. 0 - No symptoms.
3. - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to walk and attend own bodily needs without assistance. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead. |
at 90 days
|
|
Montreal Cognitive Assessment (MoCA) Score
Lasso di tempo: at baseline
|
Global cognitive screening performance will be compared between groups and collected via the Montreal Cognitive Assessment (MoCA) - blind version at presurgical baseline. The MoCA scale is used for detecting cognitive impairment. The scores range between 0 to 30 points; a score of 26 or above was considered normal. Higher values represent a better outcome. |
at baseline
|
|
Montreal Cognitive Assessment (MoCA) Score
Lasso di tempo: at 90 days
|
Global cognitive screening performance will be compared between groups and collected via the Montreal Cognitive Assessment (MoCA) - blind version at 90 days. The MoCA scale is used for detecting cognitive impairment. The scores range between 0 to 30 points; a score of 26 or above is considered normal. Higher values represent a better outcome. |
at 90 days
|
|
Montreal Cognitive Assessment (MoCA) Score
Lasso di tempo: at 12 months
|
Global cognitive screening performance will be compared between groups and collected via the Montreal Cognitive Assessment (MoCA) - blind version at 12 months. The MoCA scale is used for detecting cognitive impairment. The scores range between 0 to 30 points; a score of 26 or above is considered normal. Higher values represent a better outcome. |
at 12 months
|
|
Oral Trail Making Test - Parts A and B (executive function)
Lasso di tempo: at baseline
|
The Trail Making Test consists of 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). The patient should be instructed to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Time the patient connects the "trail." If the patient makes an error, point it out immediately and allow the patient to correct it. Results for part B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment. |
at baseline
|
|
Oral Trail Making Test - Parts A and B (executive function)
Lasso di tempo: at 90 days post-randomization
|
The Trail Making Test consists of 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). The patient should be instructed to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Time the patient connects the "trail." If the patient makes an error, point it out immediately and allow the patient to correct it. Results for part B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment. |
at 90 days post-randomization
|
|
Oral Trail Making Test - Parts A and B (executive function)
Lasso di tempo: at 12 months post-randomization
|
The trail Making Test consist of 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). The patient should be instructed to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Time the patient connects the "trail." If the patient makes an error, point it out immediately and allow the patient to correct it. Results for part B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment. |
at 12 months post-randomization
|
|
Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Span (auditory-verbal attention)
Lasso di tempo: baseline
|
The WAIS-R Digit Span test assesses short term or working memory. The examinee listens to sequences of numbers orally and then repeats them as heard, in increasing order, and in reverse order. The raw scores for "digit span" range from a minimum of 2 to a maximum of 8. For this test, the longer the span the better the cognition; therefore, the higher score is the better outcome. |
baseline
|
|
Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Span (auditory-verbal attention)
Lasso di tempo: at 90 days post-randomization
|
The WAIS-R Digit Span test assesses short term or working memory. The examinee listens to sequences of numbers orally and then repeats them as heard, in increasing order, and in reverse order. The raw scores for "digit span" range from a minimum of 2 to a maximum of 8. For this test, the longer the span the better the cognition; therefore, the higher score is the better outcome. |
at 90 days post-randomization
|
|
Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Span (auditory-verbal attention)
Lasso di tempo: at 12 months post-randomization
|
The WAIS-R Digit Span test assesses short term or working memory. The examinee listens to sequences of numbers orally and then repeats them as heard, in increasing order, and in reverse order. The raw scores for "digit span" range from a minimum of 2 to a maximum of 8. For this test, the longer the span the better the cognition; therefore, the higher score is the better outcome. |
at 12 months post-randomization
|
|
Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Symbol Substitution Test (processing speed)
Lasso di tempo: at baseline
|
The WAIS-R Digit Symbol Substitution Test (DSST) is a paper-and-pencil cognitive test that consist of number-symbol pairs. It requires the examinee to copy, into spaces below rows of numbers, the symbols that are paired to each number. The DSST score is the number of digits coded correctly in a 90-second test period |
at baseline
|
|
Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test (verbal fluency/executive function)
Lasso di tempo: at baseline
|
The D-KEFS Verbal Fluency Test is comprised of three testing conditions: Letter Fluency, Category Fluency, and Category Switching. This test measures multiple aspects of verbal productivity and cognitive flexibility. It evaluates effectiveness of novel and semantic search strategies, and assesses flexibility in the implementation of word search strategies. There are three conditions in the test in which the examinee must say as many words as they can by letter, category, and category switching prompts. |
at baseline
|
|
Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test (verbal fluency/executive function)
Lasso di tempo: at 90 days post-randomization
|
The D-KEFS Verbal Fluency Test is comprised of three testing conditions: Letter Fluency, Category Fluency, and Category Switching. This test measures multiple aspects of verbal productivity and cognitive flexibility. It evaluates effectiveness of novel and semantic search strategies, and assesses flexibility in the implementation of word search strategies. There are three conditions in the test in which the examinee must say as many words as they can by letter, category, and category switching prompts. |
at 90 days post-randomization
|
|
Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test (verbal fluency/executive function)
Lasso di tempo: at 12 months post-randomization
|
The D-KEFS Verbal Fluency Test is comprised of three testing conditions: Letter Fluency, Category Fluency, and Category Switching. This test measures multiple aspects of verbal productivity and cognitive flexibility. It evaluates effectiveness of novel and semantic search strategies, and assesses flexibility in the implementation of word search strategies. There are three conditions in the test in which the examinee must say as many words as they can by letter, category, and category switching prompts. |
at 12 months post-randomization
|
|
Incidence of Delirium
Lasso di tempo: first 7 days post-randomization
|
The incidence of delirium will be assessed daily by the Confusion Assessment Method (3D-CAM or CAM-ICU) scale, or by the presence of a delirium adverse event, during the first 7 days post-randomization. The CAM consists of 4 features: 1-Onset, 2-Inattention, 3-Disorganized thinking, and 4-altered level of consciousness. The diagnosis of delirium by CAM is based on the presence of features 1 and 2, and either 3 or 4 and involves the presence/absence of delirium, but not its severity. Any error or behavioral observation consistent with a delirium feature means that feature is present. |
first 7 days post-randomization
|
|
Duration of Delirium
Lasso di tempo: first 7 days post-randomization
|
The duration of delirium will be measured as the number of days with positive CAM assessments or delirium adverse events by 7 days post-randomization. The CAM consists of 4 features: 1-Onset, 2-Inattention, 3-Disorganized thinking, and 4-altered level of consciousness. The diagnosis of delirium by CAM is based on the presence of features 1 and 2, and either 3 or 4. |
first 7 days post-randomization
|
|
Severity of Delirium
Lasso di tempo: first 7 days post-randomization
|
The severity of delirium will be measured during daily screening using standardized algorithms for extracting symptom severity from the 3D-CAM and CAM-ICU. |
first 7 days post-randomization
|
|
Number of Patients who experience Acute kidney injury (AKI)
Lasso di tempo: within -7 days post-randomization
|
Number of Patients who experience Acute kidney injury will be assessed within 7 days post-randomization. |
within -7 days post-randomization
|
|
All-cause mortality
Lasso di tempo: within 90 days post-randomization
|
All-cause mortality within 90 days post-randomization will be assessed. |
within 90 days post-randomization
|
|
All-cause mortality
Lasso di tempo: within 12 months post-randomization
|
All-cause mortality within 12-months post-randomization will be assessed. |
within 12 months post-randomization
|
|
Length of Index Hospitalization
Lasso di tempo: at hospital discharge, up to 30 days
|
Overall length of stay for the index hospitalization post-randomization will be measured and broken down by days spent in the ICU versus days not in the ICU. |
at hospital discharge, up to 30 days
|
|
Discharge disposition
Lasso di tempo: at hospital discharge, up to 30 days
|
Discharge disposition |
at hospital discharge, up to 30 days
|
|
Readmissions rates
Lasso di tempo: first 90 days
|
Readmission rates will be calculated for the first 90 days following randomization. Hospitalizations will be classified for all causes including for cardiovascular readmissions. |
first 90 days
|
|
Readmissions rates
Lasso di tempo: up to 1 year post-randomization
|
Readmission rates will be calculated for the duration of follow-up, out to 1 year. Hospitalizations will be classified for all causes including for cardiovascular readmissions. |
up to 1 year post-randomization
|
|
Days Alive out of Hospital
Lasso di tempo: within 90 days post-randomization
|
Days alive out of hospital and nursing/rehab facilities within 90 days after randomization |
within 90 days post-randomization
|
|
Actigraphy
Lasso di tempo: 7-day period prior to index surgical procedure and Day 1 post index surgical procedure through hospital discharge
|
Actigraphy data will be collected for a period of 7 days prior to the index surgical procedure. Actigraphic monitoring employs an accelerometer the size of a watch, which each study patient will wear on the wrist. Collected for participants in substudy. |
7-day period prior to index surgical procedure and Day 1 post index surgical procedure through hospital discharge
|
|
Amount of Circadian Light
Lasso di tempo: 7-day period prior to index surgical procedure
|
A Speck light meter will be worn as a pendant while awake for a period of 7 days prior to surgery. Light measurements from light meters used as pendants are the closest to light measurements at eye level. The light meter will also be used to monitor the total amount of circadian light received by the patient. Collected for participants in substudy. |
7-day period prior to index surgical procedure
|
|
Photopic Light Levels
Lasso di tempo: 7-day period prior to index surgical procedure
|
A Speck light meter will be worn as a pendant while awake for a period of 7 days prior to surgery. Light measurements from light meters used as pendants are the closest to light measurements at eye level. The light meter will also be used to calculate photopic light levels Collected for participants in substudy. |
7-day period prior to index surgical procedure
|
|
Circadian Stimulus Values
Lasso di tempo: 7-day period prior to index surgical procedure
|
A Speck light meter will be worn as a pendant while awake for a period of 7 days prior to surgery. Light measurements from light meters used as pendants are the closest to light measurements at eye level. The light meter will also be used to calculate circadian stimulus values, Collected for participants in substudy. |
7-day period prior to index surgical procedure
|
|
Richards-Campbell Sleep Questionnaire
Lasso di tempo: Day 1 post index surgical procedure through patient discharge from the ICU (average ICU stay is 3 days)
|
Patients who are able to do so will be asked to fill out the Richards-Campbell Sleep Questionnaire (RCSQ), which is a brief 2-minute questionnaire designed for patient use in the ICU. Full score range from 0-100, with higher score indicating better sleep. Collected for participants in substudy. |
Day 1 post index surgical procedure through patient discharge from the ICU (average ICU stay is 3 days)
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Annetine C. Gelijns, PhD, Icahn School of Medicine at Mount Sinai
- Investigatore principale: Steve Messe, MD, University of Pennsylvania
- Investigatore principale: Alexander Iribarne, MD, Northwell Health
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Manifestazioni neurologiche
- Disturbi cerebrovascolari
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Malattie vascolari
- Malattia cardiovascolare
- Disordini mentali
- Malattie urogenitali maschili
- Malattie renali
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattie cardiache
- Confusione
- Manifestazioni neurocomportamentali
- Disturbi neurocognitivi
- Insufficienza renale
- Arteriosclerosi
- Malattie arteriose occlusive
- Malattia coronarica
- Ischemia miocardica
- Ictus
- Condizioni patologiche, segni e sintomi
- Segni e sintomi
- Ictus ischemico
- Delirio
- Danno renale acuto
- Disfunsione dell'arteria coronaria
- Malattie delle valvole cardiache
Altri numeri di identificazione dello studio
- STUDY-23-00417
- 5U01HL088942-16 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
Periodo di condivisione IPD
De-identified study data sets must be submitted to the designated NHLBI Program Official no later than 3 years after the end of the clinical activity (final patient follow-up, etc.) or 2 years after the main paper of the trial has been published, whichever comes first. Data are prepared by the study coordinating center and sent to the designated PO for review prior to release.
Criteri di accesso alla condivisione IPD
Anyone who wishes to access the data. Any purpose. Data are available indefinitely at (Link to be included in the URL field below).
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .